Management of CLL and the Role of Minimal Residual Disease

Management of CLL and the Role of Minimal Residual Disease

MAY 12th, 2021 - 6-7PM Eastern

Virtual Zoom


Presented by Dr. Matthew Davids, MD, MMSc

Associate Director of the CLL Center

Dana-Farber Cancer Institute



Objectives:

  • Examine the data supporting MRD as a prognostic marker

  • Highlight the increasing relevance of MRD as a response assessment tool in the context of novel therapies

  • Explore practical questions related to the use of MRD, such as how to define "undetectable" MRD

  • Present the features of different resting methodologies

  • Discuss the clinical situations and patient types in which MRD may be used to inform clinical management

Click to REGISTER

17 views0 comments